Cozaren

The increasing loss of market exclusivity for blockbuster drugs, fewer new drugs reaching the market, soaring R&D costs, and increased competition from generic and biosimilar drug are contributory factors to the economic challenges facing the pharmaceutical industry. An unrecognised opportunity for revenue generation to reverse such a downturn is strategic IP management/optimisation. With an estimated 95% of pharmaceutical patent portfolios having no identified strategic value, are you and your organisation maximising the value potential of your IP assets? At COZAREN, we view IP as more than a set of legal rights. They are also valuable commercial assets that can be leveraged to generate value and recoup R&D investments. It is, therefore, the mission of COZAREN to optimise patent asset portfolios to generate extra revenue through: • Managing, streamlining, and focusing your patent portfolio to maximise strategic value, reduce costs and shape patent prosecution; • Identifying global licensing and market opportunities; • Patent monetisation and auction; • Enhancing IP enforcement strategies and risk analyses to manage antitrust concerns and address data privacy issues. • Patent portfolio evaluation for M&A and licensing including due diligence processes and patent valuation. • Infringement monitoring using a range of traditional, online, and computational-algorithm methodologies; and, COZAREN also provides: • Patent search and analyses (pharmaceutical, biological, chemical, medical devices); • Patent mapping/landscaping; • Competitive and market intelligence research analyses; and, • Pharmaceutical product, R&D and market sales forecasting.